Literature DB >> 27775814

A subgroup cluster-based Bayesian adaptive design for precision medicine.

Wentian Guo1, Yuan Ji2,3, Daniel V T Catenacci4,5.   

Abstract

In precision medicine, a patient is treated with targeted therapies that are predicted to be effective based on the patient's baseline characteristics such as biomarker profiles. Oftentimes, patient subgroups are unknown and must be learned through inference using observed data. We present SCUBA, a Subgroup ClUster-based Bayesian Adaptive design aiming to fulfill two simultaneous goals in a clinical trial, 1) to treatments enrich the allocation of each subgroup of patients to their precision and desirable treatments and 2) to report multiple subgroup-treatment pairs (STPs). Using random partitions and semiparametric Bayesian models, SCUBA provides coherent and probabilistic assessment of potential patient subgroups and their associated targeted therapies. Each STP can then be used for future confirmatory studies for regulatory approval. Through extensive simulation studies, we present an application of SCUBA to an innovative clinical trial in gastroesphogeal cancer.
© 2016, The International Biometric Society.

Entities:  

Keywords:  Adaptive design; Bayesian nonparametrics; Dirichlet process; Enrichment designs; Personalized therapy; Reversible jump MCMC

Mesh:

Substances:

Year:  2016        PMID: 27775814      PMCID: PMC5923898          DOI: 10.1111/biom.12613

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  15 in total

1.  The mean does not mean as much anymore: finding sub-groups for tailored therapeutics.

Authors:  Stephen J Ruberg; Lei Chen; Yanping Wang
Journal:  Clin Trials       Date:  2010-07-28       Impact factor: 2.486

2.  NCI-MATCH trial pushes cancer umbrella trial paradigm.

Authors:  Asher Mullard
Journal:  Nat Rev Drug Discov       Date:  2015-08       Impact factor: 84.694

3.  Evaluating the efficiency of targeted designs for randomized clinical trials.

Authors:  Richard Simon; Aboubakar Maitournam
Journal:  Clin Cancer Res       Date:  2004-10-15       Impact factor: 12.531

Review 4.  A Bayesian approach to subgroup identification.

Authors:  James O Berger; Xiaojing Wang; Lei Shen
Journal:  J Biopharm Stat       Date:  2014       Impact factor: 1.051

5.  Randomized clinical trials with biomarkers: design issues.

Authors:  Boris Freidlin; Lisa M McShane; Edward L Korn
Journal:  J Natl Cancer Inst       Date:  2010-01-14       Impact factor: 13.506

6.  Subgroup identification based on differential effect search--a recursive partitioning method for establishing response to treatment in patient subpopulations.

Authors:  Ilya Lipkovich; Alex Dmitrienko; Jonathan Denne; Gregory Enas
Journal:  Stat Med       Date:  2011-07-22       Impact factor: 2.373

7.  EFFECTIVELY SELECTING A TARGET POPULATION FOR A FUTURE COMPARATIVE STUDY.

Authors:  Lihui Zhao; Lu Tian; Tianxi Cai; Brian Claggett; L J Wei
Journal:  J Am Stat Assoc       Date:  2013-01-01       Impact factor: 5.033

Review 8.  Clinical trial designs for predictive marker validation in cancer treatment trials.

Authors:  Daniel J Sargent; Barbara A Conley; Carmen Allegra; Laurence Collette
Journal:  J Clin Oncol       Date:  2005-03-20       Impact factor: 44.544

9.  On the efficiency of targeted clinical trials.

Authors:  A Maitournam; R Simon
Journal:  Stat Med       Date:  2005-02-15       Impact factor: 2.373

10.  Integrated transcriptional and competitive endogenous RNA networks are cross-regulated in permissive molecular environments.

Authors:  Ugo Ala; Florian A Karreth; Carla Bosia; Andrea Pagnani; Riccardo Taulli; Valentine Léopold; Yvonne Tay; Paolo Provero; Riccardo Zecchina; Pier Paolo Pandolfi
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-27       Impact factor: 11.205

View more
  6 in total

Review 1.  Bayesian Approaches to Subgroup Analysis and Related Adaptive Clinical Trial Designs.

Authors:  Ciara Nugent; Wentian Guo; Peter Müller; Yuan Ji
Journal:  JCO Precis Oncol       Date:  2019-10-24

2.  Variance prior specification for a basket trial design using Bayesian hierarchical modeling.

Authors:  Kristen M Cunanan; Alexia Iasonos; Ronglai Shen; Mithat Gönen
Journal:  Clin Trials       Date:  2018-12-07       Impact factor: 2.486

Review 3.  A State-of-the-Art Roadmap for Biomarker-Driven Drug Development in the Era of Personalized Therapies.

Authors:  Victoria Serelli-Lee; Kazumi Ito; Akira Koibuchi; Takahiko Tanigawa; Takayo Ueno; Nobuko Matsushima; Yasuhiko Imai
Journal:  J Pers Med       Date:  2022-04-21

4.  Enrichment Bayesian design for randomized clinical trials using categorical biomarkers and a binary outcome.

Authors:  Valentin Vinnat; Sylvie Chevret
Journal:  BMC Med Res Methodol       Date:  2022-02-27       Impact factor: 4.615

Review 5.  Personalized or Precision Medicine? The Example of Cystic Fibrosis.

Authors:  Fernando A L Marson; Carmen S Bertuzzo; José D Ribeiro
Journal:  Front Pharmacol       Date:  2017-06-20       Impact factor: 5.810

6.  Design and implementation of pragmatic clinical trials using the electronic medical record and an adaptive design.

Authors:  Kelly Claire Simon; Samuel Tideman; Laura Hillman; Rebekah Lai; Raman Jathar; Yuan Ji; Stuart Bergman-Bock; James Castle; Tiffani Franada; Thomas Freedom; Revital Marcus; Angela Mark; Steven Meyers; Susan Rubin; Irene Semenov; Chad Yucus; Anna Pham; Lisette Garduno; Monika Szela; Roberta Frigerio; Demetrius M Maraganore
Journal:  JAMIA Open       Date:  2018-06-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.